Browse Category

Biotechnology 8 February 2026 - 1 May 2026

Why iSpecimen Stock Whipsawed After Its 1-for-40 Reverse Split

iSpecimen Inc. shares slid to $4.80 by 14:01 Friday, down 8.2% for the day, according to Investing.com. Earlier in the session, the price swung from $4.795 to $6.77. Thursday saw a 22.5% jump, capping off a turbulent week since the company’s 1-for-40 reverse split kicked in.

1 May 2026

Biotechnology·NASDAQ:ISPC·Stock Market

Alexandria Real Estate Stock Slides as Lab-Leasing Weakness Overshadows Q1 Profit Jump

Alexandria Real Estate Equities, Inc. tumbled roughly 9% to $41.40 on Tuesday, hitting a session low of $39.52, as investors reacted to the company’s first-quarter results. Though the life-science landlord reported a sizable accounting profit, underlying operating trends proved softer than expected, according to market data.

28 April 2026

Biotechnology·Earnings Reports·NYSE:ARE·Real Estate·Stock Market

Baiya International’s $1 Million BNB Bet Sends BIYA Stock Sharply Higher

Baiya International Group Inc. is making its first move into crypto, selecting Binance Coin—known as BNB—as the debut digital asset for its new allocation strategy. The Nasdaq-listed HR tech company is drifting further from its main recruiting operations with the plan.

28 April 2026

Biotechnology·NASDAQ:BIYA·Stock Market

Intellia Therapeutics CRISPR Trial Win Puts One-Time HAE Drug On FDA Track

Intellia Therapeutics on Monday reported its experimental CRISPR gene-editing therapy led to a significant reduction in swelling attacks in a late-stage hereditary angioedema study. The company has started a rolling submission for U.S. approval of the drug, called lonvoguran ziclumeran, or lonvo-z. Designed as an outpatient infusion, lonvo-z targets a rare disorder that triggers severe swelling in areas like the face, airway, abdomen, and limbs.

27 April 2026

Biotechnology·NASDAQ:NTLA

Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

Intellia Therapeutics is slated to release top-line results Monday from HAELO, its pivotal trial of lonvoguran ziclumeran—an experimental, one-and-done therapy aimed at hereditary angioedema. The company bills this as the first-ever Phase 3 data for an in vivo CRISPR gene-editing therapy, meaning the genetic tweak happens directly in the patient rather than in lab-modified cells.

25 April 2026

Biotechnology·NASDAQ:NTLA·Pharmaceutical News·Stock Market

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly on Monday agreed to buy Boston’s Kelonia Therapeutics in a deal valued at up to $7 billion in cash, adding a fresh in vivo cell therapy play to its pipeline. The drugmaker will pay $3.25 billion upfront, with the balance subject to hitting clinical, regulatory, and commercial milestones.

21 April 2026

Biotechnology·NYSE:LLY·Pharmaceuticals

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Definium Therapeutics Inc. is heading into a heavy clinical-data stretch with fresh Wall Street backing, after Stifel analyst Paul Matteis initiated coverage of the Nasdaq-listed company with a Buy rating and a $30 price target. The focus is DT120 ODT, an orally disintegrating tablet form of lysergide D-tartrate, better known as LSD, now in late-stage trials for anxiety and depression.

18 April 2026

Biotechnology·NASDAQ:DFNT·Pharmaceutical Industry

Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Shares of Hims & Hers Health surged Wednesday, climbing roughly 14% to $24.29 as of 4:48 p.m. ET and reaching as high as $25.45 earlier in the session. The move followed news that the U.S. Food and Drug Administration plans to reconsider restrictions on several peptides—a development that could open a new growth channel for the telehealth firm.

15 April 2026

Biotechnology·NYSE:HIMS·Stock Market

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics yanked its European application for VIOKAT on Tuesday, just a day after striking a $2.9 billion cash deal to be acquired by Neurocrine Biosciences. That move halts a regulatory review Soleno had earlier projected might wrap up by mid-2026.

7 April 2026

Biotechnology·NASDAQ:NBIX·NASDAQ:SLNO·Pharmaceuticals

ImmunityBio (IBRX) stock wobbles in premarket ahead of update call — what traders are watching

ImmunityBio slipped roughly 1.4% in premarket action Tuesday, trading at $10.29. Just a day earlier, the stock finished 6.75% higher at $10.44. Huge moves have marked recent sessions; shares have now soared over 400% year-to-date.

3 March 2026

Biotechnology·NASDAQ:IBRX·Stock Market

BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next

BioCryst Pharmaceuticals slipped 2.9% to $8.50 before the bell on Monday, paring recent gains after new clinical data emerged around its hereditary angioedema pipeline.

2 March 2026

Biotechnology·NASDAQ:BCRX

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Shares of Eli Lilly and Company jumped 2.93% to finish at $1,051.99 on Friday, breaking a three-session slump and pulling ahead of a broader market that dropped. The S&P 500 slipped 0.43%, while the Dow lost 1.05%, as traders grappled with stretched valuations and renewed jitters over the speed of artificial intelligence’s impact on market leaders and laggards.

28 February 2026

Biotechnology·NYSE:LLY·Pharmaceuticals·Stock Market

GRAIL stock dips in premarket after a sharp bounce as Galleri trial fallout hangs over GRAL

GRAIL, Inc slid 5.9% to $54.70 in premarket action Friday, erasing some of Thursday’s 12.2% bounce that pushed shares to $58.10. Investors remain anxious about the Galleri blood test, the company’s key product.

27 February 2026

Biotechnology·Health News·NASDAQ:GRAL·Stock Market

CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics AG slipped 1.9% to $60.55 before the bell Friday, pulling back after an 11.85% surge in the previous session that saw the stock finish at $61.74, fueled by renewed takeover rumors.

27 February 2026

Biotechnology·Health News·NASDAQ:CRSP·Stock Market

Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics shares slipped 1.2% to $35.80 in early premarket moves Tuesday, following a 5.7% jump to $36.23 at Monday’s close. Wolfe Research kicked off its coverage with an “Outperform” and tagged a $40 price target. The stock remains below its 52-week peak of $38.69, while roughly 21.6% of the float is sold short, according to MarketBeat.

24 February 2026

Biotechnology·NASDAQ:BIIB·NASDAQ:STOK·Stock Market

Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

Gossamer Bio shares hovered near $0.42 in premarket trading Tuesday, following a brutal 80% plunge the previous day after its flagship lung-disease therapy fell short in a late-stage trial. With the stock off about $1.71 from its earlier close, traders weighed a harder path to U.S. approval, despite some isolated positives in the data.

24 February 2026

Biotechnology·NASDAQ:GOSS·Pharmaceutical News·Stock Market

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly jumped roughly 4.9% to $1,058.23 late Monday, after Novo Nordisk revealed its next-gen obesity candidate, CagriSema, didn’t measure up to Lilly’s Zepbound in direct comparison. Novo's U.S. shares dropped sharply, sliding 16.4% to $39.63.

23 February 2026

Biotechnology·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

GRAIL stock dives nearly 50% after UK Galleri trial misses key goal, raising FDA questions

GRAIL, Inc. shares tumbled 49.8% to $51.00 during Friday afternoon trading, hitting a session low of $45.51 earlier amid heavy volume.

20 February 2026

Biotechnology·NASDAQ:GRAIL·Stock Market

Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna jumped roughly 5% to $42.23 in late Friday trading. The vaccine maker managed to beat Wall Street’s revenue expectations and stuck with its 2026 growth targets, despite dealing with an FDA setback on its flu shot.

13 February 2026

Biotechnology·Earnings Reports·NASDAQ:MRNA·Pharmaceuticals·Stock Market

Roche share price set for Monday test after MS drug fenebrutinib data lands

Roche Holding is drawing attention as Swiss markets reopen Monday, following word from the drugmaker that its investigational multiple sclerosis therapy, fenebrutinib, met its primary endpoint in a late-stage trial targeting primary progressive multiple sclerosis. Roche closed out Friday at 356.40 Swiss francs, down 0.6%.

8 February 2026

Biotechnology·Healthcare News·Pharmaceuticals·Stock Market·SWX:ROG.S

Previous 1 … 3 4 5 6 7 … 21 Next

Biotechnology 8 February 2026 - 1 May 2026

Why iSpecimen Stock Whipsawed After Its 1-for-40 Reverse Split

Alexandria Real Estate Stock Slides as Lab-Leasing Weakness Overshadows Q1 Profit Jump

Baiya International’s $1 Million BNB Bet Sends BIYA Stock Sharply Higher

Intellia Therapeutics CRISPR Trial Win Puts One-Time HAE Drug On FDA Track

Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

ImmunityBio (IBRX) stock wobbles in premarket ahead of update call — what traders are watching

BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

GRAIL stock dips in premarket after a sharp bounce as Galleri trial fallout hangs over GRAL

CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

GRAIL stock dives nearly 50% after UK Galleri trial misses key goal, raising FDA questions

Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Roche share price set for Monday test after MS drug fenebrutinib data lands

TechStock² Updates

US Payrolls Down 23,000; Three-Month Hiring Slows to 20,000 Average

Nasdaq Helsinki session open as Nokia (HEL:NOKIA) investors focus on AI deal details

Airbnb (NASDAQ:ABNB) Shares Rise on AI Cost-Cutting and Higher Bookings

Joby Aviation (NYSE:JOBY) Rises in Premarket as Blade Delivers 94% of Revenue

Nasdaq Futures Rise as US Jobs Data Dents Fed Rate Hike Expectations

Top Stock Picks

Constellation Energy

AerCap

Walt Disney

AIG

Cheniere Energy

Live updates

Investment Disclaimer